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Abstract
Background: Blockade of the angiotensin (ANG) II type 1 receptor (AT1R) inhibits tumour growth in several cancers, 
including colorectal cancer (CRC) liver metastases. While AT1R blockade has been extensively studied, the potential of 
targeting the antagonistically acting AT2R in cancer has not been investigated. This study examined the effect of AT2R 
activation with the agonist CGP42112A in a mouse model of CRC liver metastases.
Results: In vitro, mouse CRC cell (MoCR) proliferation was inhibited by treatment with CGP42112A in a dose dependent 
manner while apoptosis was increased. Immunofluorescent staining for key signalling and secondary messengers, 
PLA2 and iNOS, were also increased by CGP42112A treatment in vitro. Immunohistochemical staining for proliferation 
(PCNA) and the apoptosis (active caspase 3) markers confirmed a CGP42112A-associated inhibition of proliferation and 
induction of apoptosis of mouse CRC cells (MoCR) in vivo. However, angiogenesis and vascular endothelial growth 
factor (VEGF) appeared to be increased by CGP42112A treatment in vivo. This increase in VEGF secretion by MoCRs was 
confirmed in vitro. Despite this apparent pro-angiogenic effect, a syngenic orthotopic mouse model of CRC liver 
metastases showed a reduction in liver to body weight ratio, an indication of tumour burden, following CGP42112A 
treatment compared to untreated controls.
Conclusions: These results suggest that AT2R activation might provide a novel target to inhibit tumour growth. Its 
potential to stimulate angiogenesis could be compensated by combination with anti-angiogenic agents.
Background
Metastasis to the liver is the leading cause of death in
patients with colorectal cancer (CRC)[1]. For the majority
of these patients the only treatment option is palliative
chemotherapy [2,3]. The renin angiotensin system (RAS)
is expressed in several cancers and regulates proliferation
and angiogenesis in several pathological conditions [4,5].
Experimental animal models show a stimulatory effect of
the key RAS peptide angiotensin (ANG) II through the
ANG II type 1 receptor (AT1R) on tumour growth, while
blockade this pathway inhibits tumour growth[6,7],
including in a mouse model of CRC liver metastases [8].
However, the effects of the RAS can also be mediated
through an alterative receptor, the angiotensin II type 2
receptor (AT2R), as well as an alternative peptide ANG-
(1-7) and its receptor (the MasR). The AT2R generally
exerts actions antagonistic to the AT1R including inhibi-
tion of proliferation and angiogenesis [9,10] and promo-
tion of apoptosis [11] and while AT1R blockade has been
extensively studied in the context of cancer treatment, the
potential of targeting the AT2R in cancer has not been
investigated. AT2R expression has been documented in
blood vessels of human pituitary adenomas[12] and both
the AT1R and AT2R stimulate vascular endothelial
growth factor (VEGF) secretion by rat pituitary tumour
cells [13]. AT2R activation has, however, also been shown
to inhibit VEGF signalling [9] and angiogenesis [10], sug-
gesting it can mediate both pro- and anti-angiogenic
actions. Here we targeted the AT2R via the agonist,
CGP42112A[14,15], in an orthotopic syngenic mouse
model of CRC liver metastases in which we previously
demonstrated inhibition of tumour growth following
AT1R blockade [8].
Methods
In vivo model and cell lines
T he mouse c olorectal canc er (MoCR) ce ll line used in
both the in vitro and in vivo experiments was harvested
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from a dimethylhydrazine- induced colon carcinoma in a
CBA mouse at a stage known to metastasise to the liver
[16].  In vitro, MoCR cells were maintained in RPMI/
5%FBS in an environment of 5%CO2/95% air at 37°C.
Sub-confluent cultures were used at passages 4 to 15.
Liver metastases were induced as described previously
[8,16]. Briefly, 25000 MoCR cells were injected into the
spleen of 6 to 8 week old male CBA mice and, after 3 min-
utes, the spleen removed to confine metastases to the
liver. All experiments were approved by the Austin
Health Animal Ethics Committee. Liver, kidney, and lung
samples were collected and fixed in fresh 4% PFA.
Drugs/agents and treatments
The AT2R agonist CGP42112A (Sigma-Aldrich, C160) at
0.6 μg/kg/hr (solubilised in physiological saline) was
given via osmotic mini pump (Alzet®  osmotic pumps
1004) implanted at the time of tumour induction [14,17].
Control animals received no treatment. Treatments con-
tinued from the time of tumour induction to tissue col-
lection at day 21. In vitro studies also used CGP42112A at
concentrations of 0.1 μM or 1 μM solubilised in negative
control medium (RPMI/0.1% FBS) or positive control
(RPMI/2%FBS).
CFSE and PI staining
To provide a direct measure of cell proliferation and
apoptosis a combination of CFSE (Cell Trace CFSE cell
proliferation kit, Invitrogen, #C34554) and PI (propidium
iodide) were used in a FACs analysis of cells treated for
24, 48, 72, or 120 hours. Between 4 and 8 wells across at
least 4 plates were used in analyses. Cells were stained
w i t h  C F S E  a s  p e r  m a n u f a c t u r e r ' s  i n s t r u c t i o n s  a n d
allowed to attach overnight in a 6 well plate at a density of
1 to 2 × 105 cells/well. After attachment, cells were treated
for the request time with 0.1 μM or 1 μM CGP42112A in
a background of either 0.1% FBS/RPMI (negative growth
control) or 2% FBS/RPMI (positive growth control). At
terminal time points the cells were washed with PBS and
lifted before centrifuging, washing, and suspending in
PBS. PI was added within 5 minutes of FACs analysis.
Data was analysed using Weasel (V2).
Immunohistochemistry and immunocytochemistry
Proliferation (PCNA; rabbit polyclonal, Santa Cruz sc-
7907), apoptosis (active caspase 3; rabbit polyclonal, R&D
Systems AF835), angiogenesis (CD34 neovascularisation
marker; rat anti-mouse, Abd Serotec MCA18256), and
VEGF (CalBiochem, PC315) were assessed in PFA-fixed
paraffin embedded tissues. PCNA was used at the con-
centration of 0.143 μg/ml, active caspase-3 at 1.0 μg/ml,
CD34 at 0.1 μg/ml, and VEGF at 1.5 μg/ml. Non-immu-
nized rabbit IgG (Santa Cruz, sc-2027), at 1.0 μg/ml, was
used as a negative control. Endogenous peroxidases were
blocked with 3% H2O2 and non-specific binding inhibited
with 10% normal goat serum (Zymed, 01-6201). Slides
were incubated with primary antibodies at 37°C for 1
hour and then 4°C overnight. Slides were then incubated
with the secondary antibody (Dako Envision+ Goat anti-
rabbit HRP secondary 4011) for PCNA, caspase 3 and
VEGF, and the Rat on Mouse AP-polymer kit (Biocare
Medical; RT518H) for CD34 for 1 hour at 37°C before
visualisation with DAB or, for CD34, Vulcan fast red
(Applied Medical FR805H). Slides were counterstained
with Mayer's haematoxylin. Cultured cells were grown on
superfrost slides and stained for phospholypase A2
(PLA2; Abcam, ab58375) and inducible nitric oxide syn-
thase (iNOS; Abcam, ab15323) after 24 hours of treat-
ment with 0.1 μM and 1 μM CGP42112A or control.
iNOS was used at a dilution of 1:50 and PLA2 at 1:100
over a 2 hour 37°C incubation before staining with the
fluorescently-labelled secondary (Alexa Flour 594,
A11012). UltraCruz Mounting medium (Santa Cruz Bio-
technology, sc-24941, USA) containing 4',6-diamidino-2-
phenylindole (DAPI), was used as a counter stain.
Images of stained tumours were taken using digital
light microscope (Nikon Coolscope®, Nikon Corporation,
Japan). For each tumour, 6-15 random images were taken
at 40 × magnification and the number of PCNA or cas-
pase 3 positive cells per area of viable tumour (excluding
necrotic areas, stromal intrusions and any blood vessels
or vascular lakes) determined using Image-Pro plus (ver-
sion 5). CD34 was quantified as the percentage of posi-
tively stained endothelium per area of viable tumour
(images taken at 10× magnification). For cultured cells
grown on slides, aapproximately 20 random images were
taken using the Leica DM4000 B Fluorescent microscope
and associated software. Images were analysed using
manual tag function under Image-Pro Plus and are
expressed as the percent positive cells.
Enzyme-linked immunosorbent assay (ELISA)
Conditioned media from MoCR cells (2.5 × 105 cells/ml
in a background of 0% or 0.1% FBS/RPMI) was collected
after treatment with CGP42112A (0.1 or 1 μM) for 24
hours. Two independent samples for each treatment con-
dition were assessed in duplicate. The amount of VEGF
protein secreted by treated and untreated control cells
into culture medium was measured by ELISA (R&D Sys-
tems, Mouse VEGF165 Duoset, #DY493) following the
manufacturer's instructions. Optical density of three
repeat samples was measured with the Benchmark Plus
microplate spectrophotometer (BioRad) at 450 nm absor-
bance and subtraction of 540 nm and Microplate Man-
ager 5.2.1 software.Ager et al. Cancer Cell International 2010, 10:19
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Tumour burden
The wet liver and body weights were collected from all
animals at the time of termination (day 21). The liver to
body  we igh t r a t io was  used as  a n indica t or  of  t um o ur
burden. The fixed livers were also transversely sliced into
1.5 mm sections with a multi blade fractionator and an
image of liver sections taken using Lumenera Infinity4
digital CCD camera and tumour area (mm2) and the
number of tumours per liver assessed using Image-Pro
plus 6.0.
Statistical analyses
Quantitative data are presented as mean ± SEM or box-
plots showing the minimum value, first quartile, median,
third quartile and maximum value. Statistical analyses
were conducted using SPSS (Statistical Package for the
Social Sciences, version 17, USA) or Microsoft Excel
(2003). Normally distributed data were assessed by
ANOVA. T-tests were used for comparisons between two
means with Bonferroni adjustment for multiple compari-
sons. Games-Howell tests were used if groups had
unequal variance. A probability (P) value of less than 0.05
was considered as statistically significant.
Results
CGP42112A inhibited MoCR proliferation in vitro
There was an initial delay in proliferation, probably as a
result of the change in medium from 10% FBS to either
0.1% or 2%, at the 24 hours with the majority of cells
undivided. However, after this point the average doubling
time for MoCRs growing in 2% FBS control medium was
12 hours, which extended to 14 hours in the presence of 1
μM CGP42112A, while in 0.1% FBS control the MoCR
doubling time was approximately 30 hours and this
extended to 38 hours with 1 μM CGP42112A treatment.
However, the effects of treatment were most easily seen
by examining the number of cells in each division at the
different time points. At each time point different divi-
sions were most common, with 24 hours having few
divided cells, while at 120 hours the majority of cells had
divided between 7 and 10 times. Data from these cell
majorities are discussed.
No significant difference was found in the percent of
non-dividing cells between treatments (either in a back-
ground of 0.1% FBS or 2% FBS) after 24 hours of treat-
ment (Figure 1A). However, the percentage of cells that
divided twice over 24 hours was significantly reduced by
1 μM CGP42112A treatment compared to 2% FBS con-
trol (P = 0.0370, t-test). This was not the case when cells
were cultured in a 0.1% FBS background. Similar reduc-
tions (although failing to reach significance, P between
0.058 and 0.088) were seen for 48 and 72 hour treatments
(data not shown). After 120 hours, proliferation in both
the 0.1% FBS and 2% FBS background was inhibited by
CGP42112A treatment with the higher concentration
having a greater inhibitory effect. This was evident by the
increase in the percent of treated cells in the 7th and 8th
divisions (P ≤ 0.0479) in the 2% FBS background com-
pared to the percent in the later 9 th and 10 th divisions, in
which there were more control than treated cells and sig-
nificantly so for the 10th division (P ≤ 0.0030) (Figure 1B).
In the 0.1% FBS background all divisions between 7 and
10, with the 7th significantly reduced (P = 0.049), by 1 μM
CGP42112A treatment.
CGP42112A promoted apoptosis of MOCR cells in vitro
1 μM CGP42112A treatment for 24 hours significantly
increased the percent of apoptotic MoCR cells when cul-
tured in a background of 2% FBS compared to control (P
= 0.0097, t-test; Figure 2A). Similar increases in apopto-
sis, although failing to reach significance, were seen at 48
and 72 hours. In the 0.1% FBS background, apoptosis was
increased by both 0.1 and 1 μM CGP42112A, reaching
significance for the 0.1 μM treatment (P = 0.0361). After
120 hours of treatment (Figure 2B), this increase in apop-
tosis remained evident and was significant in the 2% FBS
background (P  = 0.0323), while in the 0.1% FBS back-
ground the data was inconclusive but suggestive of a sim-
ilar trend (P = 0.0595).
CGP42112A treatment increased iNOS and PLA2 staining in 
vitro
The number of iNOS positive cells was significantly
increased by 24 hours treatment with 1 μM CGP42112A
(P  = 0.0156) and while 0.1 μM CGP42112A treatment
also increased the percent positive MoCR cells compared
to control this was not significant (Figure 3A). Similarly,
in the 2% FBS background, 1 μM treatment with
CGP42112A increased iNOS staining (P = 0.0311). PLA2,
a key signalling molecule induced by AT2R activation
[18,19], showed a similar result with increased staining
corresponding to increasing concentrations of
CGP42112A treatment (Figure 3B). This increase in
PLA2 was consistent between 2% and 0.1% FBS back-
grounds, but reached significance only in the 0.1% FBS
background (P = 0.0374)
CGP42112A treatment decreased tumour burden in vivo
A syngenic orthotopic model of CRC liver metastases was
used to assess the potential of AT2R activation (via
CGP42112A) to inhibit tumour growth. Mice were
induced with CRC liver metastases and treated
CGP42112A until termination of the experiment at day
21. Animals in the control group received no treatment.
The liver to body weight ratio was used as an indicator of
liver tumour burden. CGP42112A treatment resulted in a
significant decrease in tumour load (liver to body weight
ratio) (P = 0.021, Bonferroni t-test) (Figure 4A). ThereAger et al. Cancer Cell International 2010, 10:19
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Figure 1 CFSE staining of MoCR cells after 24 (A) and 120 (C) hours of treatment. The percent of cells at each cell division was assessed by mea-
suring the level of CFSE fluorescence by FACs. Only divisions with sufficient numbers of cells were assessed. At 24 hours almost all cells were either 
undivided or had divided twice, while by 120 hours all cells had divided at least 8 times. Proliferation was, in general, inhibited by CGP42112A treat-
ment as indicated by the lower percentage of cells with more divisions. Reduced divisions were also seen at divisions 5 to 7 at time points 48 and 72 
hours (P values between 0.058 and 0.088). Significant P values are shown with an * and solid line, while those of interest with P values between 0.1 
and 0.05 are indicated with a dotted line and no *. Data are presented as mean ± S.E.M.Ager et al. Cancer Cell International 2010, 10:19
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was no significant difference in body weight between the
control and CGP42112A-treated animals, suggesting that
could account for the decrease in liver to body weight
ratio. We also found that the average area of all tumours
in the liver for the control group was higher than that of
the treatment group (Figure 4B) and that the number of
tumours per liver was decreased by CGP42112A treat-
ment (Figure 4C). However, neither of these differences
reached significance.
CGP42112A decreased proliferation and apoptosis of 
tumour cells growing in the liver
Immunohistochemical staining for PCNA on tumour
bearing liver specimens was performed to determine if
CGP42112A could inhibit proliferation of cancer cells in
vivo. CGP42112A (P = 0.029, Games-Howell) treatment
caused a reduction in proliferation of tumour cells (Fig-
ure 5A). Immunohistochemical staining for active Cas-
pase-3 was used to distinguish apoptotic cancer cells for
quantitative analysis. CGP42112A treatment resulted in a
significant increase (P = 0.018, Bonferroni t-test) in apop-
tosis of tumour cells growing in the liver compared to
controls (Figure 5B).
CGP42112A increased secreted VGEF from MoCR cells in 
vitro
CGP42112A treatment was also associated with an
increase in CD34 staining in vivo (Figure 6A). While, this
increase failed to reach significance, evidence for a pro-
a n gi og e n i c  r o l e  o f  A T 2 R  a ct i va t i o n  is  i n d i ca t ed  b y  t h e
increase in VEGF secreted by MoCR cells both in vivo
(Figure 6B) and in vitro (Figure 6C). In vivo, VEGF stain-
ing in tumours and in tumour infiltrating cells was highly
variable in control and treated animals as well as between
tumours within animals. However, in highly stained
tumours treated animals only showed significant tumour
cell-associated VEGF, as opposed to the tumour infiltrat-
ing cells. Figure 6B inset (higher magnification) shows
VEGF-positive tumour and infiltrating cells in a tumour
from a CGP42112A treated animal, while infiltrating cells
were positive in the control. Supporting this observation,
in vitro 1 μM CGP42112A treatment increased the level
of VEGF secreted into culture medium by MoCR cells
after 24 hours (P = 0.0005, t-test) (Figure 6C).
CGP42112A treatment was not associated with any obvious 
renal or pleural abnormalities
Lung and kidney tissues were collected to ensure that
these organs, both of which are important in the systemic
RAS and which have important local RAS, were unal-
tered by treatment (Figure 7). This analysis was impor-
tant as, to the best of the authors knowledge, CGP42112A
has not yet been tested in vivo for the length of time stud-
ied here. No notable changes in either the lungs or kid-
neys between treated and control groups were found nor
was there any evidence of altered behaviour or general
condition between control and treatment groups.
Figure 2 Percent PI-positive MoCR cells. The percent of PI-positive (apoptotic) cells after 24 and 120 hours was assessed using FACs at the same 
time as CFSE analysis. Although the concentrations of CGP-421112A had their most significant effects at different times and under different back-
ground conditions, in general, CGP42112A treatment increased apoptosis. Significant P values are shown with an * and solid line, while those of in-
terest with P values between 0.1 and 0.05 are indicated with a dotted line and no *. Data are presented as mean ± S.E.M.Ager et al. Cancer Cell International 2010, 10:19
http://www.cancerci.com/content/10/1/19
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Figure 3 iNOS and PLA2 staining of MoCR cells cultured for 24 hours with CGP42112A at 0.1 or 1 μM in a background of either 0.1% FBS or 
2% FBS. Representative images are shown below. Both iNOS and PLA2 staining was increased by CGP42112A treatment. Significant P values are 
shown with an * and solid line, while those of interest with P values between 0.1 and 0.05 are indicated with a dotted line and no *. Data are presented 
as mean ± S.E.M.Ager et al. Cancer Cell International 2010, 10:19
http://www.cancerci.com/content/10/1/19
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Figure 4 Liver to body weight ratio for CGP42112A treated and untreated mice (A). Representative images are also presented. CGP42112A treat-
ment significantly decreased the liver to body weight ration, indicating reduced tumour burden in these animals compared to control. The mean area 
of tumour per sectioned liver (B) and the number of tumours per liver (C) also showed reductions with CGP42112A treatment compared to control, 
although these did not reach significance. Images of fractionated liver sections sued to count the number of tumours and tumour area are also shown, 
examples of tumours are indicated by an arrow head (D). Significant P values are shown with an * and solid line, while those of interest with P values 
between 0.1 and 0.05 are indicated with a dotted line and no *. Data are presented as mean ± S.E.M.Ager et al. Cancer Cell International 2010, 10:19
http://www.cancerci.com/content/10/1/19
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Discussion
The RAS is now known to contribute to the regulation of
tumour growth in several types of malignancy, but to date
most research has focused on the inhibitory potential of
blocking the classical RAS pathway, namely AT1R block-
ade or ACE inhibition [20-23]. A few studies have investi-
gated the effect of targeting the MasR, via infusion of its
ligand ANG-(1-7)[24-26], but no studies have examined
the potential of AT2R activation in an anti-cancer setting.
Therefore, it was the aim of this study to establish the
potential of targeting the AT2R to inhibit tumour growth
in a model of CRC liver metastases.
AT2R activation by the AT2R agonist (CGP42112A)
significantly reduced proliferation and increased apopto-
sis of MoCR cells in vitro. Supporting these results, acti-
vation of the AT2R with 0.6 μg/kg/hr of CGP42112A also
induced apoptosis and decreased proliferation of MoCR
cells growing in the mouse liver. Our results are sup-
ported by those of others demonstrating a AT2R medi-
ated increase in apoptosis of a rat pheochromocytoma
cell line (PC12W) in vitro[27] and endothelial cells in an
in vivo ischemia induced angiogenesis model[10], while
AT2R activation in rat coronary endothelial cells and vas-
cular smooth muscle cells inhibited proliferation [11].
Regulation of tumour angiogenesis is a key mechanism
by which the AT1R regulates tumour growth
[20,21,23,28]. ANG II activation of the AT1R is associated
with VEGF secretion and tumour angiogenesis is sup-
pressed following AT1R blockade [23,29]. Both the AT1R
and AT2R stimulate VEGF secretion by rat pituitary
tumour cells [13] and the AT2R is highly expressed in
intratumoural blood vessels of human pituitary ade-
nomas[12]. However, the AT2R can also inhibit VEGF
signalling [9] and angiogenesis [10]. Therefore, the role of
the AT2R in angiogenesis appears to be plastic; although
what determines whether the AT2R mediates pro- or
Figure 5 PCNA staining of CRC cells growing in the liver (A) shows that CGP42112A treatment inhibited MoCR proliferation in vivo. Immu-
nostaining for active caspase 3 also confirmed a treatment-induced increase in cancer cell apoptosis (B) in the same in vivo model. MoCR metastases 
were induced in the liver of CBA mice and allowed to grow for 21 days before fixing in PFA and immunohistochemcial analyses. Significant P values 
are shown with an * and solid line, while those of interest with P values between 0.1 and 0.05 are indicated with a dotted line and no *. Data are pre-
sented as mean ± S.E.M.Ager et al. Cancer Cell International 2010, 10:19
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Figure 6 CD34 staining of neoangiogenic vessels in treated and untreated animals inoculated with MoCR cells in the liver (A). Examples of 
high, medium, and low VEGF-expressing tumours (MoCR metastases growing in the liver) are shown for both control and treated animals (from left 
to right, respectively). Tumour (T) and infiltrating (I) cells are indicated. ELISA was used to examine VEGF secreted into medium conditioned by MoCR 
cells treated with CGP42112A at either 1 μM or 0.1 μM in a background of 0.1% FBS/RPMI. Significant P values are shown with an * and solid line, while 
those of interest with P values between 0.1 and 0.05 are indicated with a dotted line and no *. Data are presented as mean ± S.E.M.Ager et al. Cancer Cell International 2010, 10:19
http://www.cancerci.com/content/10/1/19
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Figure 7 Representative images of the kidney (upper panels) and lung (lower panel) for treated and control mice. No histological differences 
could be discerned.Ager et al. Cancer Cell International 2010, 10:19
http://www.cancerci.com/content/10/1/19
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anti-angiogenic actions is not known. Here we found a
slight increase in the level of CD34 positive staining
endothelium in the tumours of CGP42112A treated mice
and a significant increase in VEGF secreted by
CGP42112A treated MoCR cells in vitro. The lack of a
significant effect in vivo may reflect the low dose of
CGP42112A used or a contribution by the tumour
microenvironment. However, it also appeared that VEGF,
while primarily derived from tumour-infiltrating cells in
both treated and untreated animals, was produced to a
far greater extent by cancer cells in treated animals. Inter-
estingly, Clere et al. (2010) similarly found that in fibro-
sarcoma the AT2R could promote VEGF production and,
in this case, promote tumourigenesis also through
increased cell proliferation [30].
The AT2R can directly or indirectly, via stimulation of
bradykinin receptor, induce nitric oxide (NO) production
[31]. We found that CGP42112A treatment for 24 hours
significantly increased the number of iNOS positive
MoCR cells in vitro. Activation of the AT2R (either by
endogenous ligand or CGP42112A) has been shown to
increase eNOS levels in the developing pig [32] and
nNOS in the rat kidney[33]. Moreover, inhibition of
iNOS by NG-monomethyl-L-arginine mimicked AT2R
inhibition in aortic vasodilation[34]. NO can either pro-
mote or inhibit tumour progression depending on the
localisation of NOS isoforms, concentration and duration
of NO exposure, and cellular sensitivity to NO [35]. Thus,
the consequences of the iNOS upregulation are likely to
be complex, especially if stromal or host cells are also
responsive to CGP42112A treatment. However, the
increase in NO could contribute to both the increase in
neovascularisation and apoptosis described in vivo.
The increase in PLA2 was not as evident as that of
iNOS (possibly due to differences in the quality of the
antibody, as a greater standard error was seen for PLA2
stained cells). However, PLA2 is a key player in the gener-
ation of arachidonic acid and, subsequently, prostaglan-
dins which are known to stimulate angiogenesis, in part
through an increase in NO production [36]. Therefore, it
is possible that the increase in iNOS described above
reflects increased PLA2 activation by the AT2R.
Despite the pro-angiogenic effects of CGP42112A, and
perhaps as a consequence of its apoptotic and anti-prolif-
erative effects, AT2R activation resulted in a significant
reduction in the liver to body weight ratio, indicating a
reduced tumour burden in the liver. There was also a
reduction in the number of tumours and in the average
area of tumours, although these effects were not signifi-
cant. These results were observed despite the relatively
low dose of CGP42112A used (0.6 μg/kg/hr). This dose
was chosen because CGP42112A had not been used for
the length of time examined here (21 days) nor had it
been tested in the context of a cancer model and so the
potential for side effects were unknown. However, histo-
logical examination of the kidneys and lungs (as well as
the normal liver surrounding tumours) failed to find any
evidence of a deleterious effects relating to CGP42112A
treatment. In rats, doses of 6000 μg/kg/hr have been used
for up to 14 days [14], thus there is considerable scope for
higher doses to be tested in our model.
Given the promising initial results demonstrating a
reduction in MoCR proliferation and induction of apop-
tosis, reduced tumour burden, and a lack of side-effects,
additional studies confirming the potential of targeting
the AT2R in cancer are not warranted. AT2R expression
is low in most adult tissues [37], but is frequently up-reg-
ulated in patients with gastric cancer [38]. Thus, targeting
this receptor might have few side-effects. However, given
the positive correlation between tumour-angiogenesis
and poor patient outcomes, the possible increase in
angiogenesis resulting from CGP42112A treatment must
be examined further. Nevertheless, the angiogenic func-
tions of the AT2R are known to be variable and may
lessen even with higher doses of CGP42112A. Alterna-
tively, if AT2R activation does indeed increase angiogene-
sis this effect could be counteracted by a combination
with anti-angiogenic therapies.
Conclusions
The results presented here demonstrate the potential of
the AT2R as a target for inhibiting growth of CRC liver
metastases by decreasing cancer cell proliferation and
apoptosis. However, a caveat to its use would be its possi-
ble pro-angiogenic effects. Given the grim prospects for
patients diagnosed with metastatic CRC, the potential of
novel targets for improving patient outcomes is of great
significance.
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